拉米夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的对比分析-论文.pdf

《拉米夫定与阿德福韦酯治疗HBeAg阳性慢性乙型肝炎的对比分析-论文.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、·药物与临床·2013年11月第3卷第21期拉米夫定与阿德福韦酯治疗HBeAg~；H性慢性乙型肝炎的对比分析陈翠卿广东省罗定市人民医院，广东罗定527200【摘要]目的探究拉米夫定与阿德福韦酯对治疗HBeAg阳性慢性乙型肝炎的效果差异。方法选取2011年6月一2013年6月期间于我院接受门诊治疗的HBeAg阳性慢性乙型肝炎患者72例进行回顾性分析，其中36例采用拉米夫定治疗，作为拉米夫定组，36例采用阿德福韦酯治疗，作为阿德福韦酯组，连续治疗与监测24个月。观察患者24个月后血清ALT的复常率、血清HBVDNA转阴率、HBeAg消失率、HB

2、eAg转阴率等。结果拉米夫定组患者的ALT复常率、HBVDNA转阴率、HBeAg消失率、HBeAg血清转换率均随着治疗时间的加长而逐渐降低，阿德福韦酯组患者则相反，两组相比较，差异有统计学意义(P<0．05o结论拉米夫定起效快，但耐药率高，适合重症患者；阿德福韦酯虽起效慢，但2年耐药率低，对非重症患者作为首选药物。[关键词】慢性乙型肝炎；拉米夫定；阿德福韦酯；HBeAg阳性[中图分类号]R512．62[文献标识码】B[文章编号】2095—0616(2013)21—88一O2Contrastiveanalysisonthetreatmento

3、fHBeAgpositivechronichepatitisBbyusinglamivudineandadefovirdipivoxilCHENCuiqingLuodingPeople’SHospitalofGuangdongProvince，Luoding527200，China[Abstract]ObjectiveToexploretheresultdiferencesbetweenthetreatmentofHBeAgpositivechronichepatitisBbyusinglamivudineandadefovirdipivo

4、xil．Methods72HBeAgpositivechronichepatitisBpatientswhotooktheambulatorytreatmentatourhospitalduringJune2011toJune2013hadbeenselectedtomaketheretrospectiveanalysis，amongit，36patientsweretakenthetreatmentbyusinglamivudineasthelamivudinegroup，and36patientsweretakenthetreatmen

5、tbyusingadefovirdipivoxilastheadefovirdipivoxilgroup．Thecontinuoustreatmentandmonitoringhadbeentakenforthemfor24months，andafter24months，therecoveryrateofthebloodserumALT，thenegativeconversionratioofthebloodserunlHBVDNA．thefaderateofHBeAgandthenegativeconversionratioofHBeAg

6、andeteofthemwereobserved．ResultsTheALTrecoveryrate，theHBVDNAnegativeconversionratio，theHBeAgfaderate，theHBeAgseroconversionrateofthepatientsinthelamivudinegroupweregraduallyreducedwiththeincreaseoftimeoftherapy，whilethepatientsinadefovirdipivoxilgroupwerecontrary．Comparedt

7、hetwogroups，throughthestatisticalanalysisthedifferencesweresignificantfP<0．05)．ConclusionTheefectoflamivudineisrapidbutthedrugresistancerateishigh．whichissuitablef0rthecriticalpatients．And．althoughtheeffectoftheadefovirdipivoxilisslow，butthedrugresistanceratein2yearsislow，

8、whichistheprioritydrugforthenon-criticalpatients．[Keywords]ChronichepatitisB：Lamivndine；A